



Welcome to GSK  
Search

MOLECULAR PHARMACOLOGY PROGRAM

# The Jason Lewis Lab

Admissions

What can we help you find today?

[Cancer Biology](#)

[Research](#)

Search input field

[Research](#)

[Alumni](#)



Jason S. Lewis, PhD

Deputy Director, Sloan Kettering Institute – Office of Science Education and Training (OSET); Emily  
Tow Chair in Oncology

Professor

---

The Lewis lab research interests are focused on the development of radiopharmaceuticals for targeted diagnosis and treatment of cancer. By combining small- and biomolecule-based targeting agents with positron-emitting or therapeutic radioisotopes, we can interrogate molecular profiles of cancer using noninvasive nuclear imaging or treat tumors specifically with endoradiotherapy. Our research program is a molecular-imaging-based program focused on the targeting of nonstandard nuclides, with an emphasis on developing these novel radiopharmaceuticals for clinical translation. A few examples of our work are given below.

[View Lab Overview \(https://www.sloankettering.edu/research-areas/labs/jason-lewis/overview\)](https://www.sloankettering.edu/research-areas/labs/jason-lewis/overview)




## Featured News



### [At Work: Radiochemistry Service Chief Jason Lewis](#)

Radiochemist Jason Lewis works to develop new radiopharmaceuticals used in diagnosing and treating cancer.



FEATURE

### [Out of the Closet, into the Lab: Five LGBTQ Scientists Share Their Stories](#)

What's it like being LGBTQ in the world of science? We asked some MSK scientists to find out.



IN THE CLINIC

### [How Our New Particle Accelerator Will Make Cancer Imaging and Treatment More Precise](#)

The launch of a 20-ton instrument and a facility for producing radioactive imaging molecules will allow our doctors and scientists to monitor cancers in unparalleled detail.

[View All Featured News](#)

## Publications Highlights

[Nagle VL, Henry KE, Hertz CAJ, Graham MS, Campos C, Parada LF, Pandit-Taskar N,](#)

[Schietinger A, Mellinshoff IK, Lewis JS. Imaging Tumor-Infiltrating Lymphocytes in Glioblastoma with \[<sup>64</sup>Cu\]Cu-NOTA-anti-CD8-PET. Clinical Cancer Research, 27, 1958-1966, 2021.](#)

---

[Sharma SK, Suzuki M, Xu H, Korsen JA, Samuels Z, Guo H, Nemieboka B, Piersigilli A, Edwards KJ, Cheung NKV, Lewis JS. Influence of Fc modifications on biodistribution of humanized antibodies targeting L1CAM. Journal of Nuclear Medicine, 63, 629-636, 2022.](#)

---

[Tully KM, Tendler S, Carter LM, Sharma SK, Samuels ZV, Mandleywala K, Korsen JA, Delos Reyes AM, Piersigilli A, Travis WD, Sen T, Pillarsetty N, Poirier JT, Rudin CM, Lewis JS. Radioimmunotherapy Targeting Delta-like Ligand 3 in Small Cell Lung Cancer Exhibits Antitumor Efficacy with Low Toxicity. Clinical Cancer Research, 28, 1391-1401, 2022.](#)

---

[Korsen JA, Kalidindi TM, Khitrov S, Samuels ZV, Chakraborty G, Gutierrez JA, Poirier JT, Rudin CM, Chen Y, Morris MJ, Pillarsetty NVK, Lewis JS. Molecular imaging of Neuroendocrine Prostate Cancer by targeting Delta-like Ligand-3. Journal of Nuclear Medicine, 63, 1401-1407, 2022.](#)

---

[Pereira PMR, Mandleywala K, Monette S, Lumish M, Tully KM, Panikar SS, Cornejo M, Mauguen A, Ragupathi A, Keltee NC, Mattar M, Janjigian YY, Lewis JS. Caveolin-1 temporal modulation enhances antibody drug efficacy in heterogeneous gastric cancer. Nature Communications, 13, 2526, 2022.](#)

[View All Publications](#)

## People

# Jason S. Lewis, PhD

*Deputy Director, Sloan Kettering Institute – Office of Science Education and Training (OSET); Emily Tow Chair in Oncology*

Professor

- Radiochemist Jason Lewis develops molecular imaging agents for the imaging and therapy of cancer.
- PhD, The University of Kent (UK)

✉ [lewisj2@mskcc.org](mailto:lewisj2@mskcc.org)

Email Address


☎ [646-888-3038](tel:646-888-3038)

Office Phone

👤 [View physician profile](#)

Physician profile

## Members




Anne Cochrane  
Clinical Fellow



Suchitra Dara  
Graduate Student



Michele De Franco  
Research Scholar



Avraham Diament  
Research Assistant

Lab  
Alumni

Lab Affiliations

## Achievements


- Fellow, National Academy of Inventors (2025)




Olivia Friedl  
Graduate Student

- 2025 Dr. Saul Hertz Lifetime Achievement Award, SNMMI
- 2023 ACS - Glenn T. Seaborg Award for Nuclear Chemistry
- Fellow, American

Association for the Advancement of Science (FAAAS) (2022)  
2021 Gold Medal for Lifetime Achievement, World Molecular Imaging Society



Moralba Dominguez Garcia  
Research Scholar




Christine Habjan  
Graduate Student




Mohamed Hussien  
Research Technician



Paul Klauser  
Research Fellow




Jung Kuczura  
Research Technician




Tom Lemaitre  
Research Scholar

**Open**

## Positions




Olufolake Majekodunmi  
Graduate Student



Alexa Michel  
Research Technician




Candace Parker  
Research Scholar



Rachel Payne


To learn more about available postdoctoral opportunities, please visit our

[Career Center](#)



Cindy Rodriguez  
Research Scholar

To learn more about compensation and benefits for



Ana Rosu

postdoctoral researchers at MSK, please visit [Resources for Postdocs](#)

## Get in Touch

Graduate Student



Salomon Tendler  
Assistant Attending Physician



Darren Veach  
Associate Attending Chemist

✉ [lewisj2@mskcc.org](mailto:lewisj2@mskcc.org)


Lab Head Email

☎ [646-888-3038](tel:646-888-3038)


Office Phone

## Disclosures

Members of the MSK  
Community often work  
with



Juliana Welk  
Graduate Student



Aidan Wirrick  
Graduate Student

pharmaceutical, device, biotechnology, and life sciences companies, and other organizations outside of MSK, to find safe and effective cancer treatments, to improve patient care, and to educate the health care community. These activities outside of MSK further our mission, provide productive collaborations, and promote the practical application of scientific discoveries.

MSK requires doctors, faculty members, and leaders to report (“disclose”) the relationships and financial interests they have with external entities. As a commitment to transparency with our community, we make that information available to the public. Not all disclosed interests and relationships present conflicts of interest. MSK reviews all disclosed interests and relationships to assess whether a conflict of interest exists and whether formal COI management is needed.

Jason S. Lewis discloses the following relationships and financial interests:

- Alpha-9 Theranostics Inc.  
Equity; Professional Services and Activities
- BicycleTX Limited  
Professional Services and Activities
- CheMatech  
Intellectual Property Rights
- Clarity Pharmaceuticals  
Equity; Intellectual Property Rights; Professional Services and Activities
- CSRA Inc.  
Professional Services and Activities

- **Daiichi Sankyo**  
Intellectual Property Rights
- **Dialectica**  
Professional Services and Activities
- **Diaprost AB**  
Intellectual Property Rights
- **Elucida Oncology**  
Intellectual Property Rights
- **Evergreen Theragnostics**  
Equity; Professional Services and Activities (Uncompensated)
- **Goldman Sachs**  
Professional Services and Activities
- **HoneyBear Biosciences**  
Equity; Professional Services and Activities
- **Inhibrx, Inc.**  
Professional Services and Activities
- **Invicro, LLC**  
Professional Services and Activities
- **ITM Isotopen Technologien München AG**  
Professional Services and Activities
- **Journal of Nuclear Medicine**  
Professional Services and Activities
- **Luminance Biosciences, Inc.**  
Professional Services and Activities (Uncompensated)
- **Molecular Partners**  
Professional Services and Activities
- **Oncurie, Inc.**  
Equity
- **pHLIP, Inc.**  
Equity; Intellectual Property Rights; Professional Services and Activities
- **Precirix NV**  
Professional Services and Activities
- **Sanofi US Services Inc.**  
Professional Services and Activities
- **Solve Therapeutics, Inc.**  
Professional Services and Activities
- **Suba Therapeutics, Inc.**

Equity; Professional Services and Activities (Uncompensated)

- Summit Biomedical Imaging, LLC

Equity

- Telix Pharmaceuticals Limited

Equity; Professional Services and Activities (Uncompensated)

- Theragnostics, Ltd.

Intellectual Property Rights

- TRACER B.V.

Professional Services and Activities

- Wren Laboratories, LLC

Professional Services and Activities

The information published here is a complement to other publicly reported data and is for a specific annual disclosure period. There may be differences between information on this and other public sites as a result of different reporting periods and/or the various ways relationships and financial interests are categorized by organizations that publish such data.

---

This page and data include information for a specific MSK annual disclosure period (January 1, 2024 through disclosure submission in spring 2025). This data reflects interests that may or may not still exist. This data is updated annually.

Learn more about MSK's COI policies [here](#) . For questions regarding MSK's COI-related policies and procedures, email MSK's Compliance Office at [ecoi@mskcc.org](mailto:ecoi@mskcc.org) .

[View all disclosures \(https://www.sloankettering.edu/disclosures\)](https://www.sloankettering.edu/disclosures)

© 2026 Louis V. Gerstner Jr. Graduate School of Biomedical Sciences Memorial Sloan Kettering Cancer Center